JP Morgan lowered the price target for the Syneos Health Inc. (NASDAQ:SYNH) stock from “a Neutral” to “an Underweight”. The rating was released on February 13, 2023, according to finviz. We previously noted in another research note published on January 17, 2023 by Barclays that downgraded the stock from an Overweight to an Underweight with a price target of $25 for SYNH stock. The research report from Barclays has downgraded the stock from Overweight to Underweight, with a price target set at $25. The stock was downgraded by Mizuho, who disclosed in a research note on December 14, 2022, from Buy to Neutral and set the price objective to $38. In their research brief published November 07, 2022, Evercore ISI analysts downgraded the Syneos Health Inc. stock from Outperform to In-line with a price target of $27.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Syneos Health Inc. (NASDAQ:SYNH) dipped -2.93% to close Wednesday’s market session at $33.78, lower as compared to yesterday’s close. The stock price fluctuated between $32.74 and $33.93 throughout the trading session with the volume trading being 1387692 shares, which represented a significant variation when compared to the three months average volume of 1.74 million shares. The firm’s stock price fluctuated -14.22% within the last five trades and -2.51% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -38.27% in the last 6 months and -2.62% was subtracted to its value over the previous 3 months. SYNH stock is trading at a margin of -11.26%, -8.15% and -33.18% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
As of the close of trading, SYNH deals in the Healthcare domain. The stock is trading -60.47 percent below its 52-week high and 47.55 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -39. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Syneos Health Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 7.50 percent and the profit margin is 4.90 percent, and the company has reported a gross margin of 23.30 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $3.66 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for Syneos Health Inc. (NASDAQ:SYNH) is 13.10. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 8.50. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 0.68 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 0.99, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.20 percent of Syneos Health Inc. shares are owned by insiders, and 99.30 percent are held by financial institutions. Brooks Michael Lee, the Chief Operating Officer at Syneos Health Inc. (SYNH) has sold 1,002 shares of firm on Jul 28 at a price of $78.00 against the total amount of $78156.0. In another inside trade, Brooks Michael Lee, Chief Operating Officer of Syneos Health Inc. (NASDAQ:SYNH) sold 500 shares of the firm on Jul 28 for a total worth of $39000.0 at a price of $78.00. An inside trade which took place on Jul 21, Chief Operating Officer of Syneos Health Inc. Brooks Michael Lee sold 1,002 shares of firm against total price of $76152.0 at the cost of $76.00 per share.